Results 181 to 190 of about 93,221 (259)

Disarming the Hsp70–Bim Alliance: Small‐Molecule and Peptidic Disruptors of a Chaperone‐Apoptotic Switch in Cancer

ChemistryOpen, Volume 15, Issue 4, April 2026.
Targeting a nucleotide‐sensitive groove on Hsp70 that binds the Bim BH3 helix, we integrate structures, biophysics, and SAR from peptides, fragments, and phenalene‐dicarbonitrile “wedges.” These disrupt the Hsp70–Bim complex with sub‐µM cellular engagement and in vivo activity while sparing Hsp90/mortalin.
Emadeldin M. Kamel, Mohammed Al‐zharani, Lina M. Alneghery, Noha A. Ahmed, Faris F. Aba Alkhayl, Al Mokhtar Lamsabhi   +5 more
wiley   +1 more source

Retraction Note: Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells. [PDF]

Sci Rep
Ahmadi M, Ashoub MH, Heydaryan K, Abolghasemi S, Dawi EA, Khajouei G, Amiri M.   +6 more
europepmc   +1 more source

Morphofunctional Heterogeneity and Plasticity of Glioblastoma Cells Induced to Senescence by Temozolomide

Aging Cell, Volume 25, Issue 4, April 2026.
Glioblastoma cells induced to senescence by Temozolomide are heterogeneous, with the emergence of two main states, named E‐state and F‐state, which differ in cellular morphometry, survival mechanisms, and sensitivity to autophagy modulators and senolytics. These states are dynamic, with the occurrence of morphofunctional transitions.
Solon Andrades da Rosa, Henrique Quaiato de Oliveira, Laura Boose de Mendonça, Nicole Borgmann de Oliveira, Mariane da Cunha Jaeger, Luiza Cherobini Pereira, Fernanda Dittrich Pinto Oliveira, Debora Santos‐Sousa, Fernanda Saez‐Calazans, Luana Lenz, Melike Lakadamyali, Guido Lenz, Eduardo Cremonese Filippi‐Chiela   +12 more
wiley   +1 more source

Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. [PDF]

J Immunother Precis Oncol
Dişel U, Kato S, Shreenivas A, Danyeli AE, Ahluwalia MS, Kurzrock R.   +5 more
europepmc   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, Volume 183, Issue 8, Page 1640-1652, April 2026.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report. [PDF]

Case Rep Oncol
Yousefi A, Saraee E, Ghalehtaki R.
europepmc   +1 more source

MGMT upregulation mediates Temozolomide resistance conferred USP5 dependency. [PDF]

Sci Rep
Bhardwaj S, Sanjay, Sharma D, Taneja L, Yadav BK, Yadav AK.   +5 more
europepmc   +1 more source

The GPCR Connection: Linking Alzheimer's Disease and Glioblastoma

Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.
ABSTRACT Alzheimer's disease (AD) and glioblastoma multiforme (GBM) are biologically distinct age‐related brain disorders with opposing clinical phenotypes. AD is characterised by progressive neurodegeneration and cognitive decline, whereas GBM is characterised by aggressive cellular proliferation and a poor prognosis.
Ana B. Caniceiro, Sofia P. Agostinho, Luiz F. Piochi, Nícia Rosário‐Ferreira, Irina S. Moreira   +4 more
wiley   +1 more source

Human Cytomegalovirus as a Therapeutic Target in Glioma Stem Cells. [PDF]

Cells
Bou Dargham T, Vaios EJ, Lawler S, Batich K.   +3 more
europepmc   +1 more source

The immune-related microRNA miR-146b is upregulated in glioblastoma recurrence [PDF]

, 2018
Badiyan, Shahed N, Cai, Chunyu, Huang, Jiayi, Khwaja, Shariq S, Wang, Xiaowei   +4 more
core   +1 more source